Auriga Labels Jazz Pharmaceuticals (JAZZ) as Successful Orphan Drug Story; Starts Coverage at 'Buy'
Tweet Send to a Friend
Auriga initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy. PT $55.00.
Auriga analyst says, "JAZZ is a specialty ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Auriga analyst says, "JAZZ is a specialty ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
